ASH: Abecma’s survival data show why FDA wanted expert meeting on the Bristol Myers cell...

[cafead]

via Last month, Bristol Myers Squibb made the surprise announcement that the FDA will convene an advisory committee meeting to discuss the company’s bid to move the CAR-T therapy Abecma into earlier lines of treatment. Now, we know at least one reason why the FDA wants more opinions on the application.

article source